Niagen Bioscience, Inc. Total Liabilities
Niagen Bioscience, Inc. total liabilities. Based on the latest financial reports, Niagen Bioscience, Inc. (NAGE) has total liabilities worth $24.06 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See NAGE defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Niagen Bioscience, Inc. (2007–2025)
Total liabilities of Niagen Bioscience, Inc. from 2007 to 2025. This chart illustrates how Niagen Bioscience, Inc.'s total liabilities have evolved over time, based on quarterly financial data.
Niagen Bioscience, Inc. Competitors by Total Liabilities
The table below lists competitors of Niagen Bioscience, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SOL-GEL TECHN. IS-10
F:4SG
|
Germany | €5.66 Million |
|
Eureka Group Holdings Ltd
AU:EGH
|
Australia | AU$152.71 Million |
|
ANGI Homeservices Inc
NASDAQ:ANGI
|
USA | $637.85 Million |
|
Provident Agro Tbk
JK:PALM
|
Indonesia | Rp4.70 Trillion |
|
Cabio Biotech Wuhan Co Ltd
SHG:688089
|
China | CN¥183.42 Million |
|
Lotus Technology Inc.
NASDAQ:LOT
|
USA | $3.23 Billion |
|
Korea Asset In Trust Co Ltd
KO:123890
|
Korea | ₩663.03 Billion |
|
Bangkok Aviation Fuel Services Public Company Limited
BK:BAFS
|
Thailand | ฿15.47 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Niagen Bioscience, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Niagen Bioscience, Inc. balance sheet assets.
Liquidity & Leverage Metrics
Niagen Bioscience, Inc. Total Liabilities Ratios Explained
Niagen Bioscience, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.29 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Niagen Bioscience, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Niagen Bioscience, Inc. (2007–2025)
The table below shows the annual total liabilities of Niagen Bioscience, Inc. from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $29.87 Million | +34.66% |
| 2024-12-31 | $22.18 Million | -16.31% |
| 2023-12-31 | $26.51 Million | +4.42% |
| 2022-12-31 | $25.39 Million | -2.79% |
| 2021-12-31 | $26.11 Million | +19.05% |
| 2020-12-31 | $21.93 Million | +10.77% |
| 2019-12-31 | $19.80 Million | +31.54% |
| 2018-12-31 | $15.05 Million | +69.34% |
| 2017-12-31 | $8.89 Million | -9.08% |
| 2016-12-31 | $9.78 Million | -27.44% |
| 2015-12-31 | $13.47 Million | +79.22% |
| 2014-12-31 | $7.52 Million | +126.36% |
| 2013-12-31 | $3.32 Million | -34.11% |
| 2012-12-31 | $5.04 Million | +35.93% |
| 2011-12-31 | $3.71 Million | +136.04% |
| 2010-12-31 | $1.57 Million | -37.59% |
| 2009-12-31 | $2.52 Million | +7.87% |
| 2008-12-31 | $2.33 Million | +583386.75% |
| 2007-12-31 | $400.00 | -- |
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulat… Read more